whatshot

CYCC   $6.365  -5.98% Market Closed

Cyclacel Pharmaceuticals, Inc.
show_chart Advanced Chart of CYCC
Last Events:

2023-08-09 Signal in Stochastic changed from bullish reversal to bullish. The stochastic indicator is in the upper part of the neutral territory and it grows. These factors indicate that positive dynamics persists. Last signal: up-crossing the middle level.

2023-08-09 Signal in MACD changed from bearish reversal to bearish. Oscillator MACD is in the negative territory it's lower than the signal line and it crossed the zero line from the top. These factors mean that there is probably a falling trend. Last signal: down-crossing the middle level.

2023-08-06 Signal in RSI changed from bearish weakening to bearish recovery. RSI indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: exit from the overbought zone.

2023-08-06 Trend Power changed from slow to medium strength.

2023-08-05 Trend Power changed from medium strength to slow.

2023-08-04 Trend pattern changed from расходящийся клин с наклоном вверх to канал.

2023-08-04 Signal in RSI changed from bearish to bearish weakening. RSI indicator is in the lower part of the neutral territory and it heading north. These factors indicate that the upside trend is forming Last signal: exit from the overbought zone.

2023-08-03 Trend Power changed from slow to medium strength.

Current temperature: 4.08
ST: 0, Cor:

50-50 Year Forecast
Low with % probability:
Target: 4.15
High with % probability:
Analyst Recommendations:
Number of estimates 1
Target Price Mean 1.000
Mean unverified/preliminary 1.000 / 1.000
Target Price Low / High 1.000 / 1.000
Median / STD DEV 1.000 / 0.00
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total None None None
rsi Sell Sell Sell
macd None ActivelyBuy None
stoch ActivelyBuy None None
ma20 Sell None None
ma50 ActivelyBuy None None
ma100 None None ActivelyBuy
Candlestick PatternSept. 11, 2025 Doji - is formed when the open and the close are the same or very close. The body of candle is small. The length of the shadows are not important. The appearance of a Doji should alert the investor of major indecision.
ISIN US23254L8761
ceo Mr. Spiro George Rombotis
Website https://www.cyclacel.com
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.